Aldeyra Therapeutics, Inc (NASDAQ:ALDX) CEO Todd C. Brady Buys 10,000 Shares

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) CEO Todd C. Brady bought 10,000 shares of Aldeyra Therapeutics stock in a transaction dated Monday, September 9th. The shares were bought at an average cost of $4.89 per share, with a total value of $48,900.00. Following the completion of the transaction, the chief executive officer now directly owns 50,000 shares in the company, valued at $244,500. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of ALDX traded up $0.17 during trading hours on Wednesday, hitting $5.75. The company’s stock had a trading volume of 417,800 shares, compared to its average volume of 379,773. The company has a market cap of $153.90 million, a price-to-earnings ratio of -3.21 and a beta of 0.61. The business has a 50 day simple moving average of $5.04 and a two-hundred day simple moving average of $6.82. Aldeyra Therapeutics, Inc has a 52-week low of $4.31 and a 52-week high of $16.70.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.02. As a group, sell-side analysts anticipate that Aldeyra Therapeutics, Inc will post -2.01 EPS for the current year.

A number of research firms recently commented on ALDX. Zacks Investment Research cut shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 14th. Cantor Fitzgerald set a $33.00 target price on Aldeyra Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 25th. Finally, ValuEngine upgraded Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $26.79.

Institutional investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new stake in Aldeyra Therapeutics during the 2nd quarter valued at $30,000. BNP Paribas Arbitrage SA purchased a new stake in shares of Aldeyra Therapeutics during the first quarter worth $40,000. D. E. Shaw & Co. Inc. purchased a new stake in shares of Aldeyra Therapeutics during the second quarter worth $67,000. Bank of America Corp DE boosted its holdings in shares of Aldeyra Therapeutics by 139.4% in the fourth quarter. Bank of America Corp DE now owns 12,181 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 7,093 shares during the period. Finally, Ironwood Investment Management LLC bought a new position in shares of Aldeyra Therapeutics in the first quarter worth $116,000. Institutional investors and hedge funds own 61.26% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Featured Story: What is total return in investing?

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with's FREE daily email newsletter.